Related references
Note: Only part of the references are listed.A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide
Uday Kulkarni et al.
CANCER MEDICINE (2020)
Metabolic profile of leukemia cells influences treatment efficacy of L-asparaginase
Katerina Hlozkova et al.
BMC CANCER (2020)
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
Miguel A. Sanz et al.
BLOOD (2019)
Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy
Tao Li et al.
CELL DEATH & DISEASE (2018)
PML is a ROS sensor activating p53 upon oxidative stress
Michiko Niwa-Kawakita et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Varying responses of PML-RARA with different genetic mutations to arsenic trioxide
Jiangying Liu et al.
BLOOD (2016)
TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data
Liacine Bouaoun et al.
HUMAN MUTATION (2016)
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia
V. Madan et al.
LEUKEMIA (2016)
Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients
Yinjun Lou et al.
ANNALS OF HEMATOLOGY (2015)
Identification of Arsenic Direct-Binding Proteins in Acute Promyelocytic Leukaemia Cells
Tao Zhang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Systematic identification of arsenic-binding proteins reveals that hexokinase-2 is inhibited by arsenic
Hai-nan Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Acute promyelocytic leukemia: where did we start, where are we now, and the future
C. C. Coombs et al.
BLOOD CANCER JOURNAL (2015)
Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance
Ezhilarasi Chendamarai et al.
PLOS ONE (2015)
Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure
Julien Ablain et al.
NATURE MEDICINE (2014)
Resistance to Arsenic Therapy in Acute Promyelocytic Leukemia
Hong-Hu Zhu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells
Eleni D. Lagadinou et al.
CELL STEM CELL (2013)
Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukemia
Akihiro Tomita et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
F. Lo-Coco et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia
E. Lengfelder et al.
LEUKEMIA (2012)
Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment
Emi Goto et al.
BLOOD (2011)
Nutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis
Vishal M. Gohil et al.
NATURE BIOTECHNOLOGY (2010)
Acute promyelocytic leukemia: from highly fatal to highly curable
Zhen-Yi Wang et al.
BLOOD (2008)
Identification of arsenic-binding proteins in human breast cancer cells
Xinyan Zhang et al.
CANCER LETTERS (2007)
Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity
V Mathews et al.
BLOOD (2006)
Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells
P Lunghi et al.
LEUKEMIA (2005)
Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes
MJS Roussel et al.
ONCOGENE (2001)
Share Paper
